These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38902929)

  • 1. Piperacillin/tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing.
    Lodise TP; Bhavnani SM; Ambrose PG; Sader HS; Andes DR; Pogue JM
    Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38902929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of
    García-Fernández S; Bala Y; Armstrong T; García-Castillo M; Burnham CA; Wallace MA; Hardy D; Zambardi G; Cantón R
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31597745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftolozane/Tazobactam Activity Against Drug-Resistant
    Pfaller M; Shortridge D; Chen WT; Sader H; Castanheira M
    Infect Drug Resist; 2022; 15():6739-6753. PubMed ID: 36444213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin-resistant, carbapenem-susceptible Escherichia coli and Klebsiella pneumoniae.
    Kresken M; Pfeifer Y; Werner G
    GMS Infect Dis; 2021; 9():Doc08. PubMed ID: 35106270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam.
    Belley A; Morrissey I; Hawser S; Kothari N; Knechtle P
    J Glob Antimicrob Resist; 2021 Jun; 25():93-101. PubMed ID: 33746112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Piperacillin-Tazobactam Testing against
    Manuel C; Maynard R; Abbott A; Adams K; Alby K; Sweeney A; Dien Bard J; Flores II; Rekasius V; Harrington A; Kidd TS; Mathers AJ; Tekle T; Simner PJ; Humphries RM
    J Clin Microbiol; 2023 Feb; 61(2):e0161722. PubMed ID: 36719243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
    Maillard A; Delory T; Bernier J; Villa A; Chaibi K; Escaut L; Contejean A; Bercot B; Robert J; El Alaoui F; Tankovic J; Poupet H; Cuzon G; Lafaurie M; Surgers L; Joseph A; Paccoud O; Molina JM; Bleibtreu A;
    Int J Antimicrob Agents; 2023 Jul; 62(1):106809. PubMed ID: 37028731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales.
    Tamma PD; Harris PNA; Mathers AJ; Wenzler E; Humphries RM
    Clin Infect Dis; 2023 Nov; 77(11):1585-1590. PubMed ID: 36001445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin/tazobactam-resistant, cephalosporin-susceptible
    Edwards T; Heinz E; van Aartsen J; Howard A; Roberts P; Corless C; Fraser AJ; Williams CT; Bulgasim I; Cuevas LE; Parry CM; Roberts AP; Adams ER; Mason J; Hubbard ATM
    Microb Genom; 2022 Apr; 8(4):. PubMed ID: 35404783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales.
    Jousset AB; Bernabeu S; Emeraud C; Bonnin RA; Lomont A; Zahar JR; Merens A; Isnard C; Soismier N; Farfour E; Fihman V; Yin N; Barraud O; Jacquier H; Ranc AG; Laurent F; Corvec S; d'Epenoux LR; Bille E; Degand N; Plouzeau C; Guillard T; Cattoir V; Mizrahi A; Grillon A; Janvier F; Brun CL; Amara M; Bastide M; Lemonnier A; Dortet L;
    J Glob Antimicrob Resist; 2023 Mar; 32():78-84. PubMed ID: 36708769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for Updating Piperacillin-Tazobactam Breakpoints.
    Bobenchik AM
    J Clin Microbiol; 2023 Apr; 61(4):e0004223. PubMed ID: 36920195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of carriage of multidrug-resistant bacteria in dogs and cats in veterinary care and co-carriage with their owners.
    Dazio V; Nigg A; Schmidt JS; Brilhante M; Campos-Madueno EI; Mauri N; Kuster SP; Brawand SG; Willi B; Endimiani A; Perreten V; Schuller S
    One Health; 2021 Dec; 13():100322. PubMed ID: 34522760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
    Gupta V; Yu KC; Pogue JM; Watts JA; Clancy CJ
    Microbiol Spectr; 2022 Jun; 10(3):e0115822. PubMed ID: 35638777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020-2022.
    Boattini M; Bianco G; Llorente LI; Acero LA; Nunes D; Seruca M; Mendes VS; Almeida A; Bastos P; Rodríguez-Villodres Á; Gascón AG; Halperin AV; Cantón R; Escartín MNL; González-López JJ; Floch P; Massip C; Chainier D; Barraud O; Dortet L; Cuzon G; Zancanaro C; Mizrahi A; Schade R; Rasmussen AN; Schønning K; Hamprecht A; Schaffarczyk L; Glöckner S; Rödel J; Kristóf K; Balonyi Á; Mancini S; Quiblier C; Fasciana T; Giammanco A; Paglietti B; Rubino S; Budimir A; Bedenić B; Rubic Z; Marinović J; Gartzonika K; Christaki E; Mavromanolaki VE; Maraki S; Yalçın TY; Azap ÖK; Licker M; Musuroi C; Talapan D; Vrancianu CO; Comini S; Zalas-Więcek P; Michalska A; Cavallo R; Melo Cristino J; Costa C
    Int J Antimicrob Agents; 2024 May; 63(5):107115. PubMed ID: 38367844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.
    Abdelraouf K; Chavda KD; Satlin MJ; Jenkins SG; Kreiswirth BN; Nicolau DP
    Int J Antimicrob Agents; 2020 Mar; 55(3):105885. PubMed ID: 31923568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
    Shortridge D; Streit J; Pfaller M; Tulloch M; Chen WT; Castanheira M
    J Glob Antimicrob Resist; 2022 Dec; 31():98-103. PubMed ID: 35988706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosfomycin Disk Diffusion Testing among Klebsiella pneumoniae Results in Frequent Inner Colonies and Categorical Disagreement Based on Conflicting Breakpoint Organization Recommendations.
    Bixby ML; Salay JM; Krueger AR; Mathers AJ; Hirsch EB
    Microbiol Spectr; 2023 Mar; 11(2):e0336322. PubMed ID: 36877020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
    Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
    Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality associated with third-generation cephalosporin resistance in Enterobacterales bloodstream infections at eight sub-Saharan African hospitals (MBIRA): a prospective cohort study.
    Aiken AM; Rehman AM; de Kraker MEA; Madrid L; Kebede M; Labi AK; Obeng-Nkrumah N; Nyamwaya B; Kagucia E; Cocker D; Kawaza K; Lester R; Iregbu KC; Medugu N; Nwajiobi-Princewill PI; Dramowski A; Sonda T; Hemed A; Fwoloshi S; Ojok D; Scott JAG; Whitelaw A;
    Lancet Infect Dis; 2023 Nov; 23(11):1280-1290. PubMed ID: 37454672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers.
    Sader HS; Mendes RE; Kimbrough JH; Kantro V; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad058. PubMed ID: 36861086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.